SpringWorks Therapeutics reported strong revenue growth from OGSIVEO, achieving $61.5 million in net product revenue for Q4 2024. The company also received FDA approval for GOMEKLI and ended the year with $461.9 million in cash and equivalents. However, it reported a net loss of $77.3 million for the quarter.
Achieved $61.5 million in Q4 2024 net product revenue for OGSIVEO.
Received FDA approval for GOMEKLI for NF1-PN treatment.
Reported a net loss of $77.3 million for Q4 2024.
Ended 2024 with $461.9 million in cash, cash equivalents, and marketable securities.
SpringWorks expects continued revenue growth with expanded commercialization efforts, but challenges remain in cost management and profitability.
Analyze how earnings announcements historically affect stock price performance